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Abstract 
The extensive collection of bacteria cohabiting within the host collaborates with human 
functions and metabolisms in both health and disease. The fine equilibrium of commensals is 
tightly controlled and an imbalance (“dysbiosis”) in the gut microbiota can play different 
roles in human disease. The development of new genome sequencing techniques has allowed 
a better understanding of the role of human gut microbiota. This led to the identification of 
numerous metabolites produced in the gut, which have been suggested to play a role in 
human disease. Among these, TMAO appears to be of particular importance as a risk factor 
and potentially as a causative agent of various pathologies, most remarkably cardiovascular 
and disease and other associated conditions. Mechanistic links are yet to be established, 
however, increased levels of TMAO have been shown to augment the risk of developing 
renal failure, metabolic syndrome, diabetes mellitus, heart failure, hypertension, 
atherosclerosis and dyslipidemia ultimately leading to increased risk of serious 
cardiovascular events. This article reviews the potential impact of TMAO in human 
cardiovascular disease.  
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Introduction 
Cardiovascular disease is the first cause of mortality worldwide.1 Defining risk factors for 
prevention and control of its prognosis is of utmost importance. The rise of genome 
sequencing technologies has provided opportunities to characterize potential effect of 
commensal organisms on pathogenesis of human disease.2, 3 Of course, this brought great 
interest for investigation of the putative role of gut microbiota in cardiovascular risk.  
This article analyses evidence gathered in recent years regarding the role of microbiota in 
cardiovascular disease, as reported in original studies and meta-analyses. The aim of this 
review is to provide a critical view on the topic, with a specific focus on trimethylamine 
oxide (TMAO), a metabolite derived from choline and L-carnitine, which are nutrients found 
in ingested red meat and other animal products. 
 
The microbiota in health and disease 
Microbiota is a collection of organisms that coexist within the host, mainly colonizing 
nutrient rich sites of the gastrointestinal tract and utilizing anaerobic metabolism to survive.4 
While benefiting from the colonization, gut microbiota also has a role in the saccharolytic 
and proteolytic digestion pathways.4 Gut microbiota performs multiple functions around the 
body, including stimulation of the immune system, promoting innate immunity against 
pathogens 4 and regulating mucosal barriers.5 Aside from their commensal physiological 
roles, gut microbiota can have unfavorable effects on different organs in the body. With all 
these factors in place, gut microbiota has different roles in the general health of individuals.6  
 
The human gut mainly hosts five phyla i.e. Actinobacteria, Bacteroidetes, Verrucomicrobia, 
Proteobacteria and Firmicutes.6 The relative abundance and ratios of each phyla among 
individuals has been studied in relation to morbidity risk. Studies have shown that an increase 
of Firmicutes to Bacteroidetes ratio can cause obesity, metabolic syndrome and 
hypertension.7 Factors such as diet, antibiotic use and lifestyle can affect ratios differently in 
different individuals.  
 
Gut microbiota can also have an impact through its biologically active metabolites. Multiple 
products are released by bacterial fermentation, such as short chain fatty acids (SCFAs), 
choline metabolites, bile acids (BAs) and uremic toxins.8-10 Pathogenic mechanisms of 
different metabolites on cardio-metabolic disorders are highlighted in Figure 1.  
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Figure 1: Gut Microbiota and Cardiovascular Disease 
Adapted from Ahmadmehrabi et al.11  
 
A metabolite that has caught the interest of scientists and clinicians is the choline metabolite 
trimethylamine (TMA), derived from choline and L-carnitine, which are nutrients found in 
ingested red meat and other animal products. TMA is oxidized in the liver to trimethylamine 
oxide (TMAO) by Flavin-containing monooxygenases (FMO), proven to show detrimental 
effects on the cardiovascular system through multiple pathways, later discussed in this 
review.10, 12 
 
TMAO and all-cause mortality  
Recent meta-analyses have shown that elevated levels of plasma TMAO are associated with 
increased all-cause mortality (HR: 1.91; 95% CI:1.40-2.61),13 even after correcting for 
conventional cardiovascular risk factors and chronic kidney disease.13, 14 
Of interest, controversy exist regarding the impact of geographical location on the results of 
the studies showing a link between TMAO and impaired clinical outcomes,14 as race, 
ethnicity and dietary habits, may have an impact on the findings. In a recent study, 
Schiattarella et al.13 stratified study individuals to assess whether the relation between 
increased all-cause mortality and elevated levels of TMAO persists across countries and 
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found this to be the case. They also carried out the first dose-response meta-analysis for 
TMAO and all-cause mortality, revealing an increased relative risk with increased 
concentrations (RR: 1.07, mortality increase by 7.6% per each 10 mol/L increment of 
TMAO), but this was a nonlinear association. With the notable exception of pre-existing 
CAD, that strengthens the relation, the association between elevated plasma TMAO levels 
and increased mortality seems not to be altered by population baseline characteristics.  
Nonetheless, the distribution of TMAO has no standardized values, since studies have not 
been carried out in the general population; thus, the possibility to establish a systematic 
association is limited, until randomized multicenter general population studies are performed. 
Due to its wide impact on the host metabolism, TMAO levels influence morbidity too.13, 14  
 
The link between TMAO and obesity, metabolic syndrome and type 2 diabetes mellitus 
Studies have shown that predisposition to obesity might be linked to a higher ratio of 
Firmicutes to Bacteroidetes.15 Conversely, other trials have shown that obesity itself alters the 
microbial flora.16 This modification in gut microbiota composition, leads to an alteration in 
gut microbiota metabolites i.e. increased secondary bile acids, short chain fatty acids, 
lipopolysaccharides and TMAO.17 As previously mentioned, all these metabolites have been 
described to have a pathogenic role in human health.  In fact, tightly linked with obesity, they 
seem to be concurrently causing metabolic syndrome.18 Perry et al. showed that increased 
production of metabolites (acetate) stimulates a parasympathetic response consequently 
promoting abnormal glucose-stimulated insulin secretion, increased ghrelin secretion, 
hyperphagia, and eventually, obesity, metabolic syndrome and their sequelae.18 Based on  
these assumptions, a study demonstrated that fecal microbial transplantation from lean male 
donors (allogenic) to patients with metabolic syndrome improved insulin sensitivity after six 
weeks, compared to autologous fecal transplant.19 
 
Gut microbiota is also known to differ in composition and to have various grades of 
microbial dysbiosis in patients with type 2 diabetes mellitus compared with individuals 
without diabetes. In particular, patients with T2DM have decreased quantity of butyrate-
producing bacteria and augmented Lactobacillus spp.20, 21 It is now know that a decrease in 
butyrate producing bacteria, normally protective against different type of diseases and T2DM 
complications, leads to reduced insulin sensitivity and promotes the development of 
diabetes.20, 22 
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Chronic kidney disease 
A large cohort study by Kim et al. involving 2529 patients found that individuals with CKD 
have very high levels of TMAO, with increasing levels among higher CKD stage patients.23 
Tang et al assessed 3687 CKD patients and found that TMAO was associated with a 1.7-fold 
increase (HR 1.70, 95%CI 1.25–2.30, p<0.001) in all-cause mortality after adjusting for 
traditional CVD risk factors and stratifying results according to median TMAO levels. The 
study further explored the effects of TMAO on animal models and concluded that TMAO 
promotes renal fibrosis and kidney dysfunction.24  It is not known however whether TMAO 
contributes to the development of CKD or pre-existing CKD favors a decreased clearance of 
TMAO thus resulting in high concentrations of the metabolite. Randomized controlled trials 
are required to answer this question. 
 
Hypertension 
Being the most prevalent modifiable cardiovascular risk factor, hypertension became a matter 
of interest to microbiota research teams. Studies have suggested a possible impact of 
microbial gut dysbiosis on blood pressure control. In particular, Yang et al. observed an 
imbalance in the Firmicutes to Bacteroidetes ratio and a decrease in butyrate and acetate 
producing bacteria both in spontaneously hypertensive rats and in patients, albeit the latter 
were small cohorts.25 Along these lines, overweight and obese women with higher butyrate 
producing bacteria typically have lower blood pressure readings.26 Thus, according to these 
results, the gut microbiota appears to have effects on blood pressure control. These findings 
indicate that communication channels probably exist between the gut enteric nervous system 
and the CNS through sympathetic innervation and metabolites signaling, as proposed by 
Santisteban et al.27  In fact, it appears that intestinal wall permeability allows metabolites 
produced by gut microbes to have an effect on distant organs and systems.28 
Authors have suggested that antibiotics and probiotics could be used for better pressure 
control, particularly in patients with resistant hypertension 29 and gut microbial dysbiosis.30   
 
Dyslipidemia 
Gut microbiome is known to have influence on body mass, triglycerides and high-density 
lipoproteins. It has also been reported that the effect of microbiota on triglycerides and HDL 
is independent from patient’s body mass, suggesting a direct mechanistic effect of its 
metabolites.31 This biological mechanism, though, remains unknown.17 What is known, 
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however, is that TMAO-generating enzyme FMO3 reduces reverse cholesterol transport, 
alters tissue cholesterol and sterol metabolism and changes bile acids composition and pool 
size. This happens through modification of bile acid secretion, reduction of intestinal 
cholesterol absorption and limitation of hepatic oxysterols and cholesteryl esters’ production. 
Thus, the microbiota could also affect cholesterol levels thus probably contributing to 
atherogenesis.  Warrier et al. 32 also showed that in FMO3 knock out models, liver-X receptor 
function is stimulated, thus promoting reverse cholesterol transport and ameliorating 
cholesterol levels and equilibrium. These findings depict the FMO3 /TMAO pathway as a 
key player in the regulation of cholesterol levels and metabolism potentially, playing an 
important pro-atherogenic role.  
 
 
Atherosclerosis   and myocardial infarction 
One of the strongest links between gut microbiota and human disease has been demonstrated 
in relation to atherosclerosis. In fact, after developing the hypothesis that bacterial infection 
could be a cause of atherosclerotic plaque formation, Ott el al. investigated atheromatous 
plaques from heart disease patients and healthy donors for bacterial DNA identification. They 
detected a very high variety of bacterial signature in the material, among which 
Staphylococcus, Proteus vulgaris, Klebsiella pneumoniae, and Streptococcus species featured 
prominently. Although these observations do not represent proof that the microbiota plays a  
causative role in atherosclerosis, they suggest that bacterial agents could act as an additional 
factor accelerating disease progression.33 The same concept, but involving oral microbiota, 
has been demonstrated to be plausible by Koren et al. 2 Their trial also proposed to use 
bacteria from the oral cavity as disease markers for atherosclerosis, since the bacterial DNA 
present in the analyzed material, was the same of the taxa in patients’ oral cavity and gut 
microbiota.  
Other than bacterial signatures, also higher levels of TMAO have exhibited a positive 
correlation with atherosclerotic plaque size. Wang et al. showed that TMAO and betaine 
upregulate scavenger receptors on macrophages, consequently promoting atherogenesis; 
TMAO itself fosters cholesterol accumulation and foam cell formation.8  Furthermore, 
Karlsson et al., through meta-genomic sequencing, showed that the composition of gut 
microbiota seems to be different in patients with symptomatic atherosclerosis, compared to 
asymptomatic ones. This could be due to the fact that, through their metabolites, bacteria can 
promote a pro-inflammatory state in the host, fostering clinical instability and plaque rupture, 
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leading to symptoms and an increased number of cardiovascular events. According to their 
study, more symptomatic patients have decreased levels of Rosebarium species in their stool 
samples, species known to promote anti-inflammatory effects in humans.34 
 
Taken all of the above information together it seems plausible that microbial dysbiosis could 
lead to high levels of TMAO, plaque instability and myocardial infarction.  Indeed, Lam et al. 
demonstrated that the composition of intestinal microbiota might have an impact of the 
severity of myocardial infarction in rats.35 A mechanistic link was proposed in these and 
other studies, administering broad spectrum antibiotics in mice with induced myocardial 
infarction. Compared to untreated mice, those receiving antibiotic treatment showed smaller 
size of myocardial infarction and improved left ventricular function during recovery time. 
This finding was linked to a reduction in leptin concentrations, associated with the use of 
antibiotics.22   Similarly, Gan et al., again in an experimental animal study, demonstrated that 
probiotic administration i.e. Lactobacillus rhamnosus GR-1 in coronary artery occlusion mice 
models lessened post-infarction myocardial hypertrophy.36 The mechanism found was leptin 
reduction, as postulated by other investigators previously..  
Heart failure 
It has been hypothesized that inflammatory mechanisms seen in heart failure patients could 
be due to decreased cardiac output to the gut leading to disruption of the intestinal barrier, 
allowing the passage of bacteria and endotoxins.37, 38 These toxins activate toll-like receptors 
fueling the inflammatory process and possibly fostering atherogenesis.39 Another possible 
mechanistic link between heart failure and high TMAO levels is that TMAO prolongs the 
effect of angiotensin, inducing adverse cardiac remodelling.40  From the information 
summarized above it is apparent that there are bidirectional effects of TMAO on heart failure. 
 
Different studies confirmed that concentrations of TMAO and its precursors (betaine and 
choline) are higher in patients with chronic heart failure and levels correlate with New York 
Heart Association (NYHA) classes.38, 41, 42 A study by Tang et al. showed that there is a 
correlation between TMAO and brain natriuretic peptide (BNP), a marker of heart failure (r = 
0.23; p < 0.001). Elevated TMAO levels are predictive of worsening 5-year mortality risk 
after adjusting for traditional risk factors and BNP (HR: 2.2; 95% CI: 1.42 to 3.43; p < 
0.001).38 Tang et al. showed that in 112 chronic heart failure patients, only higher TMAO 
rather than choline or betaine levels resulted in adverse clinical events independent of age 
and BNP levels (HR 1.46 [1.03 2.14], p=0.03).42 
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Increased Major Adverse Cardiovascular Events and morbidity  
Major Adverse Cardiovascular Events (MACE) development in relation to gut metabolites 
have been investigated in several clinical studies, and further assessed and reviewed in 
various qualitative and quantitative meta-analyses. 
A meta-analysis by Heianza et al. reviewing 19 prospective studies estimated the risk of 
MACE incidence and all cause death in association with TMAO levels. Results showed a 
strong increase in relative risk of both outcomes in patients with higher TMAO levels (62% 
increase RR in MACE, 63% increase in all-cause death).43 Interestingly, TMAO levels came 
as an independent predictor of MACE, not being influenced by past cardiovascular history 
and diabetes in comparable populations. This counter-intuitive finding was further supported 
by dose response analyses that conveyed a dose dependent relation between TMAO and its 
precursors and the incidence of MACE.  
A meta-analysis by Schiattarella et al. reported similar outcomes underlying that the presence 
of CKD as a comorbidity does not seem to influence results.13 
As previously mentioned, the postulated potential mechanisms underlying this increased 
relative risk are several, i.e. enhanced development of larger, more unstable atherosclerotic 
plaques; alteration of hepatic cholesterol and lipid metabolism; fostering a pro-inflammatory 
condition and promotion of endothelial dysfunction with heightened platelet activity due to 
modified calcium signaling. 
It has to be said however that a case of reverse causality cannot be excluded. At present, no 
study demonstrated whether the composition of the gut microbiota is affected after an 
ischemic event, thus increasing TMAO production, or high TMAO plasma levels are the 
primary cause of augmented risk of CAD.  It should be underlined that most clinical studies 
investigating the matter have been carried out in known CVD and high-risk patients. Still, no 
standardized normal level and life-trend of TMAO has been studied in the general population 
and no prospective cohort study has been carried out in patients at different levels of 
cardiovascular risk.  
 
Is gut bacterial dysbiosis a therapeutic target? 
Several therapeutic interventions have been investigated to further assert the effect of TMAO 
on cardiovascular disease. Diet interventions have been utilized in high risk individuals to 
improve chronic metabolic disorders. As mentioned earlier, the composition of microbiota is 
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affected by the individual’s dietary habits. Studies have shown that a diet resulting in 
decreased synthesis of TMAO has beneficial effects.44-47 Despite these findings, other studies 
have shown that the composition of gut microbiota remains practically unchanged over a 
person’s lifetime.22  Am emerging therapeutic intervention is the use of Fecal Microbiota 
Transplantation (FMT) to manage cardio-metabolic disorders. This strategy aims to displace 
intestinal pathogens and introduces the fecal content of healthy individuals into high risk 
patients. The effects of autologous fecal transfer –Transfer of one’s own feces acting as 
placebo- and allogenic fecal transfer -transfer from healthy lean individuals-  were compared 
in metabolic syndrome patients, and it resulted in a significant improvement of hepatic and 
peripheral insulin sensitivity after 6 weeks follow-up.48  Despite initial encouraging studies, 
limitations are still to be overcome regarding FMT, particularly the introduction of 
endotoxins, as well as rejection.49, 50 
 
Theories surrounding the potential of TMAO as a causative agent for platelet aggregation 
could potentially prove to be extremely beneficial. This is due to the fact that targeting 
TMAO’s presence is speculated to have an anti-aggregation effect comparable to that of 
conventional antiplatelet drugs, with less bleeding risk.10 
 
Furthermore, intervening with probiotics and prebiotics has shown to influence the intestinal 
microbiota content. Probiotics are beneficial bacterial organisms that inhabit the gut while 
prebiotics are non-bacterial food ingredients that affect the microbial community. Probiotics 
have shown to positively influence glucose intolerance associated with developing metabolic 
syndrome and decrease the amount of toxins produced by the gut during metabolism. 
 
Gaps in knowledge and future perspectives 
Even though many of the studies mentioned in this review highlight the potential importance 
of TMAO and its metabolites levels, numerous gaps in knowledge do exist.   Firstly, no 
detailed mechanistic or causal evidence has been provided on its role in morbidity, the 
development of atherosclerosis and/or increased incidence of MACE. Moreover, work is 
needed to identify potential molecular targets as well as defining other therapeutic strategies.  
Secondly, studies are required to define TMAO plasma levels that represent increased risk 
and to establish correlation between concentrations of the metabolite and increased 
cardiovascular risk, as well as risk of disease in general. Matters like inhibition of TMA 
production in order to decrease TMAO levels and -possibly- beneficially affect the heart 
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failure phenotype.  Of great interest, it would be to understand the mechanisms and clinical 
significance of TMAO elevation in CKD patients, which has been associated with worsening 
of renal fibrosis and kidney dysfunction.22  Moreover, investigating the relative risk of new 
incidence of CVD in previously healthy individuals with high TMAO plasma levels would be 
of utmost importance to clarify the role of this metabolite in human disease.  
All the clinical trials performed thus far have involved hospitalized patients and high-risk 
individuals, probably resulting in bias regarding result interpretation and making it difficult to 
extrapolate these findings to the general population or unselected patient groups who are at 
lower risk.  
 
Future perspective 
Possibility of using TMAO as a novel biomarker in primary prevention of cardiovascular 
disease could be further established in mechanistic studies. This will lead to a shift from 
traditional CVD risk factors and open doors for new treatments and modulation therapies 
specifically targeted towards gut microbiota. 
Possible interventions such as the use of antibiotics to alter the microbial composition of the 
gut have been studied in young mice, where adiposity was increased in subjects that were 
administered with a subtherapeutic dose of an antibiotic. This is further proven by studies that 
have shown that obesity can be influenced by the use of antibiotics in infancy, showing that 
there could be a possible mechanistic link between the development of obesity and microbial 
composition in the gut. 
Another future possible intervention in gut microbiota modulation is targeting enzymes 
within the TMAO pathway, such as TMA lyase, which influence the plasma levels of TMAO 
as shown through in vivo studies on mice.51 This grows the potential of controlling 
metabolite production leading to a further improvement in cardiovascular risk management. 
 
Conclusion 
The links between TMAO and the development of CVD as well as related conditions have 
been investigated in several studies. Further large randomized studies, however, are 
necessary in unselected population as well as in carefully characterized patient subgroups to 
establish the true importance of TMAO as a marker of disease, a causative agent and a 
therapeutic target.  
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